% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm May 6, 2013 7:51 PM Flag

    Why Cannacord and Wedbush agree on $12

    This morning Goldman said the S&P 500 is now trading near fair value based on several methodologies.
    The explosive biotech rally of the last 2 years will end with a sector rotation (which I dont pretend to know when), but one thing is for sure.- Sectors ,all sectors are ultimately affected by the S&P

    Insmed will have no profits for years( 3 is BCS),also watch for the coming dilution.- it will happen unless they partner.

    Say nothing of competing with pharma powerhouses Novartis and Gilead,Cannacord and Wedbush agree
    on the orphan for CF- it will not surpass 100 Million. (Wedbush 65-75 M 2018)at full market penetration.
    (btw- that is a strong 25-30 % of the total market.)

    Ultimately the results may change things - to speculate above what is known is the height of folly in biotech.
    Now I just put our resident clowns on ignore and I see $250 off label and I dont have to even guess which idiot it was...anyway
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
16.59+0.55(+3.43%)Nov 25 4:00 PMEST